Latest Breaking News On - Peptide drug candidate - Page 1 : comparemela.com

Bulletin from the Annual General Meeting in Oncopeptides AB (publ)

Bulletin from the Annual General Meeting in Oncopeptides AB (publ)
marketscreener.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from marketscreener.com Daily Mail and Mail on Sunday newspapers.

United kingdomEuropean unionPeptide drug candidateMarketing authorizationNasdaq stockholm

Oncopeptides and Vector Pharma FZCO Announce Collaboration to Provide Pepaxti to Patients in the Middle East and North Africa

DUBAI, United Arab Emirates and STOCKHOLM, Sweden, March 27, 2024 (GLOBE NEWSWIRE) Oncopeptides AB (STO: ONCO), a biotech company focused on difficult-to-treat cancers, and Vector Pharma FZCO (“Vector”) today announced a collaboration to commercialize Oncopeptides’ flagship drug Pepaxti (melphalan flufenamide) in the Middle East and North Africa (“MENA”) countries of Saudi Arabia, Qatar, UAE, Bahrain, Kuwait, Oman, Algeria, Tunisia, Morocco, Libya, Lebanon, and Iraq. Under the terms of this e

United kingdomSaudi arabiaUnited statesUnited arab emiratesHealth care providersWorld orphan drug allianceEuropean unionVector pharmaMiddle eastNorth africaPartner patrickSofia heigisPeptide drug candidateGreater chinaSouth koreaMarketing authorization

Oncopeptides announces successful price negotiations for Pepaxti in Germany

Oncopeptides announces successful price negotiations for Pepaxti in GermanyStockholm – September 26, 2023 – Oncopeptides AB (publ), a biotech company focused on difficult-to-treat cancers, today announces that following negotiations between Oncopeptides and the German Federal Joint Committee National Ass.

United kingdomDavid augustssonEuropean unionCorporate affairsStatutory health insurance fundsSofia heigisPeptide drug candidateMarketing authorizationSmall capNasdaq stockholm

Oncopeptides AB - Holger Lembrer will leave his role as Chief Financial Officer at Oncopeptides

Oncopeptides AB , a biotech company focused on difficult-to-treat cancers, today announced that Holger Lembrer, Chief Financial Officer has decided to leave Oncopeptides to pursue a new role in. | June 15, 2023

United kingdomHolger lembrerRolf gulliksenMonica shawEuropean unionNasdaq stockholmChief financial officerPeptide drug candidateMarketing authorizationSmall capNews publishingOncopeptides ab publ stock exchangePress releaseOle onco se0009414576

Annual General Meeting in Oncopeptides AB

The shareholders in Oncopeptides AB , reg. no. 556596-6438, with registered office in the municipality of Stockholm, are hereby given notice to attend the Annual General Meeting to be held at. | April 24, 2023

United kingdomVastra tradgardsgatanRolf gulliksenEuropean unionAnnual general meetingAnnual generalPeptide drug candidateMarketing authorizationSmall capNasdaq stockholmNews publishingOncopeptides ab publ stock exchangePress releaseEld onco se0009414576